Relevant bibliographies by topics / GLP-1 Agonists

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'GLP-1 Agonists'

Author: Grafiati
Published: 3 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'GLP-1 Agonists.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "GLP-1 Agonists"

1

Dharmaraj, B. "A brief review on newer Glucagon like Peptide-1 analogues." International Journal of Preclinical and Clinical Research 1, no. 1 (2020): 26–34. http://dx.doi.org/10.51131/ijpccr/v1i1.7.

Full text
Abstract:
GLP-1 (Glucagon like Peptide-1) receptor agonists have been shown to be effective in the treatment of type 2 diabetes mellitus (T2DM). Although the first GLP-1 receptor agonist, Exenatide, was approved in the year 2000, other agents with a longer duration of action that do not require twice-daily dosing are now being developed. Indeed, Liraglutide, a once-daily GLP-1 receptor agonist, was approved in 2010, a once-weekly extended-release formulation of Exenatide (Exenatide ER) was approved in 2011 and now more recently Semaglutide, an oral GLP 1 receptor agonist was approved for medical use in
APA, Harvard, Vancouver, ISO, and other styles
2

Viby, Niels-Erik, Marie S. Isidor, Katrine B. Buggeskov, Steen S. Poulsen, Jacob B. Hansen, and Hannelouise Kissow. "Glucagon-Like Peptide-1 (GLP-1) Reduces Mortality and Improves Lung Function in a Model of Experimental Obstructive Lung Disease in Female Mice." Endocrinology 154, no. 12 (2013): 4503–11. http://dx.doi.org/10.1210/en.2013-1666.

Full text
Abstract:
The incretin hormone glucagon-like peptide-1 (GLP-1) is an important insulin secretagogue and GLP-1 analogs are used for the treatment of type 2 diabetes. GLP-1 displays antiinflammatory and surfactant-releasing effects. Thus, we hypothesize that treatment with GLP-1 analogs will improve pulmonary function in a mouse model of obstructive lung disease. Female mice were sensitized with injected ovalbumin and treated with GLP-1 receptor (GLP-1R) agonists. Exacerbation was induced with inhalations of ovalbumin and lipopolysaccharide. Lung function was evaluated with a measurement of enhanced pause
APA, Harvard, Vancouver, ISO, and other styles
3

Triplitt, Curtis, and Carolina Solis-Herrera. "GLP-1 Receptor Agonists." Diabetes Educator 41, no. 1_suppl (2015): 32S—46S. http://dx.doi.org/10.1177/0145721715607981.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Clark, LaDonna. "GLP-1 receptor agonists." JAAPA 37, no. 4 (2024): 1–4. http://dx.doi.org/10.1097/01.jaa.0001007388.97793.41.

Full text
Abstract:
ABSTRACT Type 2 diabetes mellitus (T2DM) is a chronic medical condition affecting millions of individuals worldwide. The burden of disease is significant, as demonstrated by high morbidity and mortality and billions of healthcare dollars spent. The pathophysiology of T2DM is complex, with eight primary deficits. In recent years, an increased focus has been placed on incretin hormones, such as glucagon-like peptide-1 (GLP-1) for its glucose-lowering benefits. Several FDA-approved short-acting and long-acting GLP-1 receptor agonists (GLP-1 RAs) are available in the United States for the treatmen
APA, Harvard, Vancouver, ISO, and other styles
5

Elchouemi, Mohanad, Mostafa Eysha, Mariia Kasianchyk, et al. "The effect of GLP-1 receptor agonists on outcomes in metastatic renal cell carcinoma patients undergoing immune checkpoint inhibitor therapy: A retrospective multi-institutional US cohort study." Journal of Clinical Oncology 43, no. 16_suppl (2025): 4559. https://doi.org/10.1200/jco.2025.43.16_suppl.4559.

Full text
Abstract:
4559 Background: Glucagon-like peptide-1 (GLP-1) receptor agonists have played a pivotal role in the management of type 2 diabetes (T2DM). At the same time, immune checkpoint inhibitor (ICI) therapy remains one of the mainstay treatments for metastatic renal cell carcinoma (mRCC). There has been a scarcity of research on the effect of GLP-1 receptor agonists on ICI efficacy in cancer patients. This study presents the first real-world analysis of the effect of GLP-1 receptor agonists on outcomes in mRCC patients receiving ICI therapy. Methods: Data was retrospectively collected from TriNetX, a
APA, Harvard, Vancouver, ISO, and other styles
6

Goldenberg, Ronald M., Hwee Teoh, and Subodh Verma. "Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data." Current Opinion in Cardiology 38, no. 6 (2023): 539–45. http://dx.doi.org/10.1097/hco.0000000000001084.

Full text
Abstract:
Purpose of review Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are approved for the management of type 2 diabetes (T2D) and obesity, and some are recommended for cardiorenal risk reduction in T2D. To enhance the benefits with GLP-RA mono-agonist therapy, GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor co-agonists are in development to capitalize on the synergism of GLP-1 and GIP agonism. We review the mechanisms of action and clinical data for GLP-1/GIP receptor co-agonists in T2D and obesity and their potential role in cardiovascular protection. Recent findings Tirze
APA, Harvard, Vancouver, ISO, and other styles
7

Trakoonsenathong, Ronnakrit, Ching-Feng Chiu, and Charupong Saengboonmee. "Glucagon-like peptide 1 receptor agonist: A potential game changer for cholangiocarcinoma." World Journal of Gastroenterology 30, no. 34 (2024): 3862–67. http://dx.doi.org/10.3748/wjg.v30.i34.3862.

Full text
Abstract:
Glucagon-like peptide-1 receptor (GLP-1R) agonist, a subgroup of incretin-based anti-diabetic therapies, is an emerging medication with benefits in reducing blood glucose and weight and increasing cardiovascular protection. Contrarily, concerns have been raised about GLP-1R agonists increasing the risk of particular cancers. Recently, several epidemiological studies reported contradictory findings of incretin-based therapy on the risk modification for cholangiocarcinoma (CCA). The first cohort study demonstrated that incretin-based therapy was associated with an increased risk of CCA. Later st
APA, Harvard, Vancouver, ISO, and other styles
8

Sato, Tetsuhiko, Emi Ohara, Chikafumi Ozone, et al. "A Possible Advantage of Glucagon-Like Peptide 1 Receptor Agonist in Kidney Transplant Recipients With Type 2 Diabetes." Journal of the Endocrine Society 5, Supplement_1 (2021): A405—A406. http://dx.doi.org/10.1210/jendso/bvab048.826.

Full text
Abstract:
Abstract Diabetic kidney disease (DKD), a devastating complication of diabetes, is one of the leading causes of end stage kidney disease (ESKD). Kidney transplantation provides superior outcomes for ESKD patients with type 2 diabetes, giving opportunities to be free from dialysis, but needs lifetime immunosuppressive medications to avoid graft kidney rejection. Post-transplant hyperglycemia, however, remains to be unsolved, because immunosuppressive agents, including glucocorticoids and calcineurin inhibitors, may result in impaired insulin secretion and sensitivity. Safe and promising anti-di
APA, Harvard, Vancouver, ISO, and other styles
9

Kopp, Katherine O., Yazhou Li, Elliot J. Glotfelty, David Tweedie, and Nigel H. Greig. "Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration." Biomolecules 14, no. 7 (2024): 872. http://dx.doi.org/10.3390/biom14070872.

Full text
Abstract:
Glucagon-like peptide-1 (GLP-1)-based drugs have been approved by the United States Food and Drug Administration (FDA) and are widely used to treat type 2 diabetes mellitus (T2DM) and obesity. More recent developments of unimolecular peptides targeting multiple incretin-related receptors (“multi-agonists”), including the glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) and the glucagon (Gcg) receptor (GcgR), have emerged with the aim of enhancing drug benefits. In this study, we utilized human and mouse microglial cell lines, HMC3 and IMG, respectively, together with the huma
APA, Harvard, Vancouver, ISO, and other styles
10

Alicic, Radica Z., and Joshua J. Neumiller. "Incretin Therapies for Patients with Type 2 Diabetes and Chronic Kidney Disease." Journal of Clinical Medicine 13, no. 1 (2023): 201. http://dx.doi.org/10.3390/jcm13010201.

Full text
Abstract:
Since the early 2000s, an influx of novel glucose-lowering agents has changed the therapeutic landscape for treatment of diabetes and diabetes-related complications. Glucagon-like peptide-1 (GLP-1) receptor agonists represent an important therapeutic class for the management of type 2 diabetes (T2D), demonstrating benefits beyond glycemic control, including lowering of blood pressure and body weight, and importantly, decreased risk of development of new or worsening chronic kidney disease (CKD) and reduced rates of atherosclerotic cardiovascular events. Plausible non-glycemic mechanisms that b
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "GLP-1 Agonists"

1

Ekenberg, Marie. "Swedish diabetes patients’ experiences of using GLP-1 receptor agonists (GLP-1 RAs) : A qualitative interview study." Thesis, Uppsala universitet, Institutionen för farmaceutisk biovetenskap, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-434750.

Full text
Abstract:
Background: The world prevalence of diabetes mellitus in 2019 was 8.3%, out of which 85-90% have type 2 diabetes mellitus (T2DM). Numerous drugs for treating T2DM are approved, and one of the newer classes of drugs are GLP-1 receptor agonists (GLP-1 RAs). In Sweden during 2015 to 2019, the number of patients using GLP-1 RAs has increased by 280%. Despite this, few studies have explored the experiences of patients using these drugs.  Aim: The aim of this study was to gain knowledge about how patients diagnosed with T2DM experience and understand their treatment with GLP-1 RAs in Sweden.  Method
APA, Harvard, Vancouver, ISO, and other styles
2

Babateen, Omar M. "GABA signaling regulation by GLP-1 receptor agonists and GABA-A receptors modulator." Doctoral thesis, Uppsala universitet, Fysiologi, 2016. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-282431.

Full text
Abstract:
GABA (γ-aminobutyric acid) is the main neuroinhibitory transmitter in mammalian brains.  It binds to GABA-A and GABA-B receptors. The GABA-A receptors are ligand-gated chloride channels. A variety of GABA-A receptor agonists and antagonists have been developed to study the GABA-mediated inhibition and to explore new medications. In this thesis I have examined the role of GABA in brain tumors and the effects of the metabolic hormone GLP-1 on GABAergic signaling in neurons. I studied if GABA-A receptors subunits were expressed and formed functional ion channels in the glioblastoma cell line U304
APA, Harvard, Vancouver, ISO, and other styles
3

Hart, Nathaniel. "Combinatorial Targeting of the Glucagon-Like Peptide-1 And Sulfonylurea-1 Receptors Using a Complimentary Multivalent Glucagon-Like Peptide-1/Glibenclamide Ligand for the Improvement of β-Cell Targeting Agents and Diabetic Treatment". Diss., The University of Arizona, 2013. http://hdl.handle.net/10150/311363.

Full text
Abstract:
A scourge of Type I and Type II diabetes impacts the health of hundreds of millions worldwide. The number and prevalence of diabetics are expected to rise dramatically in the next two decades. Diabetes is defined by chronic hyperglycemia which can result in a number of detrimental and costly metabolic, renal, cardiovascular and neurological disorders. Identification of at risk individuals and effective blood glucose management are critical to improving diabetic outcomes and preventing hyperglycemic complications. Diabetes prevention and treatment is limited by the understanding of islet functi
APA, Harvard, Vancouver, ISO, and other styles
4

Holmes, Sophie. "The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on cell viability, ADAM10 maturation and the proteolysis of ADAM10 substrates in SH-SY5Y cells." Thesis, Lancaster University, 2018. http://eprints.lancs.ac.uk/129821/.

Full text
Abstract:
Arguably the causative agent of Alzheimer's disease (AD), amyloid beta (Aβ)- peptides, are generated by sequential proteolysis of the amyloid precursor protein (APP) by β- and γ-secretase activities. Alternatively, APP can be processed nonamyloidogenically by an α-secretase activity that cleaves within the Aβ-domain, precluding the formation of intact Aβ-peptides and liberating a neuroprotective fragment, sAPPα. This latter proteolytic event is catalysed by a disintegrin and metalloproteinase (ADAM) 10. Recent research has suggested that glucagon-like peptide-1 (GLP-1) analogues; Lixisenatide,
APA, Harvard, Vancouver, ISO, and other styles
5

Ferreira, Mari Cassol. "Análise da resposta hormonal pancreática antes e após tratamento com GLP-1 mimético em indivíduos com diabetes tipo 2 portadores da variante rs7903146 do gene TCF7L2." Universidade de São Paulo, 2013. http://www.teses.usp.br/teses/disponiveis/5/5135/tde-01112013-113904/.

Full text
Abstract:
Introdução: O gene TCF7L2 (Transcription Factor 7-Like 2) codifica o fator de transcrição de mesmo nome que, tem importante papel na via Wnt de sinalização intra celular. A via Wnt é constituída por proteínas de integração e ligação dos processos de diferenciação e multiplicação celulares, interagindo com os fatores TCF, e ativando a expressão de genes relacionados ao TCF7L2, sendo este amplamente expresso em vários tecidos. Dados epidemiológicos atuais não deixam dúvidas quanto à forte associação de polimorfismos do gene TCF7L2 com o diabetes tipo 2 (DM2) em diferentes etnias. Apesar de serem
APA, Harvard, Vancouver, ISO, and other styles
6

Hoguet, Vanessa. "Optimisation de nouveaux agonistes topiques intestinaux du récepteur aux acides biliaires TGR5 pour le traitement du diabète de type 2." Thesis, Lille 2, 2017. http://www.theses.fr/2017LIL2S024/document.

Full text
Abstract:
Le récepteur membranaire TGR5 (Takeda G Protein-coupled Receptor 5), est un récepteur ubiquitaire sensible aux acides biliaires. Il est exprimé dans de nombreux tissus et organes dont l’intestin (dans les cellules entéroendocrines L), la vésicule biliaire, les muscles lisses et squelettiques, le tissu adipeux brun et dans certaines cellules immunitaires. Des études menées in vitro et in vivo chez l’animal ont montré des effets bénéfiques de l’activation de TGR5 sur l’homéostasie énergétique et glucidique. Il est maintenant communément admis que les effets bénéfiques de TGR5 sur l'homéostasie d
APA, Harvard, Vancouver, ISO, and other styles
7

Lasalle, Manuel. "TGR5, cible thérapeutique pour le traitement du diabète de type 2 et ses complications métaboliques : de la chimie aux effets biologiques." Thesis, Lille 2, 2015. http://www.theses.fr/2015LIL2S023/document.

Full text
Abstract:
Les acides biliaires sont depuis longtemps connus pour leur propriété d’agents solubilisant des graisses et des vitamines liposolubles, permettant ainsi une absorption efficace de ces nutriments lors de la digestion. Depuis les années 2000, plusieurs équipes ont montré que ces molécules étaient également dotées de propriétés de signalisation, en particulier via l’activation de deux récepteurs : le récepteur nucléaire FXR, et le récepteur membranaire TGR5. Le récepteur TGR5 est exprimé dans de très nombreux tissus, dont les muscles lisses et squelettiques, le tissu adipeux brun, la vésicule bil
APA, Harvard, Vancouver, ISO, and other styles
8

Harkavyi, Alexander. "Neuroprotective effect of GLP-1 receptor agonist Exendin-4 in rat models of Parkinson's disease." Thesis, University College London (University of London), 2009. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.515060.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Yamane, Syunsuke. "GLP-1 receptor agonist attenuates endoplasmic reticulum stress-mediated β-cell damage in Akita mice". Kyoto University, 2011. http://hdl.handle.net/2433/147341.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Mounger, David Kyle, Kynlee Hillard, Brooke Tipton, Grayson D. White, and Matthew R. Zahner. "GLP-1 agonist liraglutide increases metabolic- and cardiovascular-related sympathetic activity of the central nervous system." Digital Commons @ East Tennessee State University, 2019. https://dc.etsu.edu/asrf/2019/schedule/58.

Full text
Abstract:
Metabolic syndrome is associated with pathologies that include type 2 diabetes, hypertension, and dyslipidemia, all of which increase the risks of heart disease. Glucagon-like peptide (GLP-1) is a hormone produced by intestinal enteroendocrine L‑cells. GLP-1 increases insulin sensitivity, augments glucose-dependent insulin secretion, and suppresses glucagon release. GLP-1 also works centrally to decrease appetite and increase metabolism. Evidence suggests that the beneficial effect is mediated by metabolically related sympathetic neurons within the hypothalamus. Although the hypothalamus conta
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "GLP-1 Agonists"

1

Meier, Juris J., Baptist Gallwitz, and Francesco Giorgino, eds. Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist with Both Injectable and Oral Formulations. Frontiers Media SA, 2021. http://dx.doi.org/10.3389/978-2-88971-350-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "GLP-1 Agonists"

1

Madsbad, Sten, and Jens J. Holst. "Treatment with GLP-1 Receptor Agonists." In Endocrinology. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-45015-5_20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Madsbad, Sten, and Jens J. Holst. "Treatment with GLP-1 Receptor Agonists." In Endocrinology. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-27317-4_20-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Gallwitz, Baptist. "GLP-1 Agonists and Dipeptidyl-Peptidase IV Inhibitors." In Diabetes - Perspectives in Drug Therapy. Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-17214-4_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Müller-Wieland, D., J. Brandts, M. Verket, N. Marx, and K. Schütt. "Glycaemic Control in Diabetes." In Prevention and Treatment of Atherosclerosis. Springer International Publishing, 2021. http://dx.doi.org/10.1007/164_2021_537.

Full text
Abstract:
AbstractReduction of glucose is the hallmark of diabetes therapy proven to reduce micro- and macro-vascular risk in patients with type 1 diabetes. However glucose-lowering efficacy trials in type 2 diabetes didn’t show major cardiovascular benefit. Then, a paradigm change in the treatment of patients with type 2 diabetes has emerged due to the introduction of new blood glucose-lowering agents. Cardiovascular endpoint studies have proven HbA1c-independent cardioprotective effects for GLP-1 receptor agonists and SGLT-2 inhibitors. Furthermore, SGLT-2 inhibitors reduce the risk for heart failure
APA, Harvard, Vancouver, ISO, and other styles
5

Bandeira, Francisco, Fábio Moura, and Bruna Burkhardt Costi. "GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes." In Endocrinology and Diabetes. Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-8684-8_30.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bandeira, Francisco, Fábio Moura, Bruna Burkhardt Costi, and Ana Carolina S. M. Cardoso. "GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes." In Endocrinology and Diabetes. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-90684-9_31.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ahn, Jung-Mo, Sun-Young Han, Eunice Murage, and Martin Beinborn. "Rational Design of Peptidomimetics for Class B GPCRs: Potent Non-Peptide GLP-1 Receptor Agonists." In Advances in Experimental Medicine and Biology. Springer New York, 2009. http://dx.doi.org/10.1007/978-0-387-73657-0_55.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Nauck, Michael A., Wolfgang E. Schmidt, and Juris J. Meier. "The Incretin Modulators – Incretin Mimetics (GLP-1 Receptor Agonists) and Incretin Enhancers (DPP-4 Inhibitors)." In Pharmacotherapy of Diabetes: New Developments. Springer US, 2007. http://dx.doi.org/10.1007/978-0-387-69737-6_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Karaburgu, Sulbiye. "Current Approach of Diabetes Mellitus in Obese Patients." In Current Perspective on Diabetes Mellitus in Clinical Sciences. Nobel Tip Kitabevleri, 2023. http://dx.doi.org/10.69860/nobel.9786053359111.8.

Full text
Abstract:
The current approach to managing diabetes mellitus in obese patients focuses on a comprehensive strategy that addresses both conditions simultaneously. Central to this approach is weight management through lifestyle modifications, including dietary changes and increased physical activity. Caloric restriction, with an emphasis on balanced nutrition that limits simple sugars and unhealthy fats while promoting fiber-rich foods, plays a crucial role. Regular exercise helps improve insulin sensitivity and facilitates weight loss. Pharmacotherapy may include medications that not only lower blood glu
APA, Harvard, Vancouver, ISO, and other styles
10

Bertoccini, Laura, and Marco Giorgio Baroni. "GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection." In Advances in Experimental Medicine and Biology. Springer International Publishing, 2020. http://dx.doi.org/10.1007/5584_2020_494.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "GLP-1 Agonists"

1

Bernard, Elise S. C., Jacky Metcalfe, Isabelle Sermadiras, et al. "GLP-1 and GIP receptors co-agonists." In 35th European Peptide Symposium. Prompt Scientific Publishing, 2018. http://dx.doi.org/10.17952/35eps.2018.244.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hjørringgaard, Claudia, Jens Christian Nielsen, Mads Mørup Nygaard, et al. "StreaMLine - Machine learning guided development of novel GLP-1 receptor agonists." In 37th European Peptide Symposium. The European Peptide Society, 2024. http://dx.doi.org/10.17952/37eps.2024.p1143.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hojs, Radovan, Robert Ekart, Sebastjan Bevc, and Nina Vodošek Hojs. "Obesity and cardionephrology – guidance on the management." In 7th International Congress of Cardionephrology KARNEF 2025. Punta Niš, 2025. https://doi.org/10.46793/karnef25.204h.

Full text
Abstract:
There is a pandemic of obesity worldwide. There is compelling evidence that obesity is associated with chronic kidney disease (CKD). Studies have shown that high body mass index is strongly related to the risk of CKD, progression of CKD and end-stage renal disease, also after adjustment for age, sex, race, smoking status, comorbidities, and laboratory tests. Obesity increases the risk of death in people without CKD. In non-dialysis-dependent CKD patients, the association between body-mass index and weight with mortality is controversial. In end-stage renal disease patients, obesity is paradoxi
APA, Harvard, Vancouver, ISO, and other styles
4

Lin, Zhiyue. "Analysis of Possible Ingredient and Manufacture Steps of Oral GLP-1 Receptor Agonists." In The International Conference on Biomedical Engineering and Bioinformatics. SCITEPRESS - Science and Technology Publications, 2022. http://dx.doi.org/10.5220/0011205700003443.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Tent, Michiel. "GLP-1 agonists induce weight loss and alleviate headache in idiopathic intracranial hypertension." In EAN Congress 2023. Medicom Medical Publishers, 2023. http://dx.doi.org/10.55788/380d2b76.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

HASSAN, Neeran F. "USING INCRETIN IN TREATMENT OF DIABETES MELLITUS DISEASE." In IV.International Scientific Congress of Pure,Appliedand Technological Sciences. Rimar Academy, 2022. http://dx.doi.org/10.47832/minarcongress4-29.

Full text
Abstract:
Incretin hormones are gut peptides secreted in response to nutrient ingestion, which play a key role in the regulation of islet function and blood glucose levels. In humans, the major incretin hormones are glucagon-like peptide (GLP)-1 and glucose- dependent insulinotropic polypeptide (GIP), and together they fully account for the incretin effect which is defined as the phenomenon whereby orally ingested glucose elicits a much greater insulin response than that obtained when glucose is infused intravenously to give identical blood glucose levels. there is evidence to suggest that impairments i
APA, Harvard, Vancouver, ISO, and other styles
7

Chaaban, M. R., D. Hoying, and D. Kaelber. "GLP-1 Agonists Reduce Functional Endoscopic Sinus Surgery Rates in Chronic Rhinosinusitis Patients With Obesity." In American Thoracic Society 2024 International Conference, May 17-22, 2024 - San Diego, CA. American Thoracic Society, 2024. http://dx.doi.org/10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5395.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Esteban, S. "5PSQ-009 Adequacy of use and effectiveness of glp-1 receptor agonists in real clinical practice." In Abstract Book, 23rd EAHP Congress, 21st–23rd March 2018, Gothenburg, Sweden. British Medical Journal Publishing Group, 2018. http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.363.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Chhabra, Puneet, and Rituraj Singh. "IDDF2025-ABS-0165 Unmasking aspiration risks: a propensity matched odyssey of GLP-1 receptor agonists and colonoscopy." In Abstracts of the International Digestive Disease Forum (IDDF), Hong Kong, 5 – 6 July 2025. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2025. https://doi.org/10.1136/gutjnl-2025-iddf.221.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Costa, M., S. O’Leary, A. Price, C. Young, V. Srinivasan, and P. Kan. "O-070 Impact of GLP-1 agonists on stroke, SAH, and ICH: a propensity-matched multi-institutional cohort study." In SNIS 22nd Annual Meeting Abstracts. BMJ Publishing Group Ltd., 2025. https://doi.org/10.1136/jnis-2025-snis.70.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "GLP-1 Agonists"

1

Stone, Siobhan, and Matthew Doane. New Antiobesity Medications, GLP-1, and GIP Receptor Agonists and their Anaesthetic Implications. World Federation of Societies of Anaesthesiologists, 2024. http://dx.doi.org/10.28923/atotw.535.

Full text
Abstract:
The new anti-obesity medications have an impressive ability to assist with weight management and diabetic control. This tutorial outlines the various types of GLP-1 receptor agonists on the market, how they work, their side effects and their evolving peri-operative management.
APA, Harvard, Vancouver, ISO, and other styles
2

Xie, Yunhui, and Peng Pang. A Systematic Review and Network Meta-Analysis: Effect of of GLP-1 drugs on weight loss in obese people. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.6.0074.

Full text
Abstract:
Review question / Objective: 1、Whether GLP-1 drugs have weight loss effect on obese people ? 2、Which GLP-1 drugs are most effective in weight loss among obese people ? Condition being studied: Obesity is an important public health issue that has been on the rise over the last decades. It calls for effective prevention and treatment. Bariatric surgery is the most effective medical therapy for weight loss in morbid obesity, but we are in need for less aggressive treatments. Glucagon-like-peptide-1 receptor agonists are a group of incretin-based drugs that have proven to be productive for obesity
APA, Harvard, Vancouver, ISO, and other styles
3

Berg, Sara, Hannah Lillicraf, Suzanne Rose, and Eric Nemec. The effects of discontinuing GLP-1 receptor agonists on body habitus - A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2024. http://dx.doi.org/10.37766/inplasy2024.2.0004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Tsai, Wen-Wen, Kuan-Hsien Lu, Jheng-Yan Wu, et al. GLP-1 receptor agonists in Parkinson’s disease progression: A systematic review and meta-analysis with trial sequential analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2024. http://dx.doi.org/10.37766/inplasy2024.11.0119.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Zhao, Jing, Ouyang Jing, Xiaming Wang, Jing Li, Liwei Jia, and Ping Liu. Efficacy and safety of GLP-1 receptor agonists on motor function for patients with Parkinson's disease: a meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2025. https://doi.org/10.37766/inplasy2025.6.0034.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Zhao, Fang, Haoshu Wang, Shenguang Li, Hezhang Yun, and Wenbo Su. The Effects of GLP-1 Receptor Agonists on Metabolic Inflammatory Markers in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2025. https://doi.org/10.37766/inplasy2025.4.0020.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

yu, luyou, jinping yang, xi meng, and yanhua lin. Effectiveness of the gut microbiota-bile acid pathway (BAS) in the treatment of Type 2 diabetes: A protocol for systematic review and meta analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.7.0117.

Full text
Abstract:
Review question / Objective: To systematically evaluate the efficacy of the intestinal microbiome - bile acid pathway (BAS) in the treatment of T2DM. Condition being studied: Bile acids (BAs), an important component of bile, are also metabolites derived from cholesterol and promote intestinal absorption and transportation of dietary lipids . Studies have shown that bile acid receptor agonists can promote glP-1 secretion and improve glucose metabolism in preclinical mouse models of obesity and insulin resistance , which may become a new therapeutic target for Type 2 diabetes. However, no system
APA, Harvard, Vancouver, ISO, and other styles
8

Yeh, Jia-Ai, Yu-Chang Liu, and Huei-Kai Huang. Relative Risk of Nephrolithiasis in Type 2 Diabetes Patients Using Sodium-Glucose Cotransporter 2 Inhibitors Compared to Those Using DPP-4 Inhibitors or GLP-1 Receptor Agonists: A Protocol of Systematic Review and Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2024. http://dx.doi.org/10.37766/inplasy2024.10.0087.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Jorgina, Acevedo, Otero Aleida, Rojas Angel, and Pastrana Arias Ariel (Director). Innovación y desarrollo de fármacos para el tratamiento de la obesidad: un agonista del receptorGLP-1. Universidad de Cartagena, 2024. https://doi.org/10.32997/11227/18498.

Full text
Abstract:
La innovación y desarrollo de fármacos para el tratamiento de la obesidad, específicamente de los agonistas del receptor GLP-1, ha mostrado un progreso significativo. La información mostrada nos indica que el agonista del receptor semaglutina es eficaz para reducir el peso en personas obesas ofreciendo un enfoque prometedor en el tratamiento en la obesidad y sus comorbilidades. La obesidad es una enfermedad asociada con serias consecuencias metabólicas para la salud, incluyendo la diabetes tipo 2, dislipidemia, enfermedades cardiovasculares y cáncer. A pesar de años de extensa investigación en
APA, Harvard, Vancouver, ISO, and other styles
10

Vahratian, Anjel, and Antonia Warren. GLP-1 Injectable Use Among Adults with Diagnosed Diabetes: United States, 2024. National Center for Health Statistics (U.S., 2025. https://doi.org/10.15620/cdc/174616.

Full text
Abstract:
This report describes the percentage of adults with diagnosed diabetes who were taking an injectable glucagon-like peptide-1 (GLP-1) receptor agonist at the time of the interview by selected characteristics based on data from the 2024 National Health Interview Survey (NHIS).
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'GLP-1 Agonists' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography